Rare cancers of the head and neck area in Europe

B.A.C. Van Dijk a,*, G. Gatta b, R. Capocaccia c, D. Pierannunzio c, P. Strojan d, L. Licitra b, The RARECARE Working Group

ARTICLE INFO

Article history:
Received 5 May 2011
Received in revised form 17 August 2011
Accepted 22 August 2011
Available online 1 November 2011

Keywords:
Rare cancer
Head and neck cancer
Cancer of eye and adnexa
Cancer of middle ear
Population based study
Incidence
Prevalence
Survival
Europe

ABSTRACT

The RARECARE project has proposed a different and more detailed grouping of cancers, based on localisation and histological type, in order to identify rare entities with clinical meaning. RARECARE gathered data on cancer patients diagnosed from 1978 to 2002 and archived in 76 population-based cancer registries, all of which had vital status information available up to at least 31st December 2003. This study provides incidence, prevalence and survival rates for rare head and neck epithelial (H&N) cancers.

Among the rare H&N cancers, those of oral cavity had the highest annual crude incidence rate of 48 per million, followed by oropharynx and ‘major salivary glands and salivary gland type tumours’ (28 and 13 per million, respectively). Incidence rates of epithelial tumours of nasal cavities, nasopharynx, eye and adnexa and middle ears were all lower than 5 per million. The prevalence for all investigated entities was lower than 35 per 100,000. The 5-year relative survival rates ranged from 40% for epithelial cancer of oropharynx to 85% for epithelial cancer of eye and adnexa. Survival rates were lower for men and for patients aged ≥65 years. With few exceptions, the lowest and highest survival figures were observed for Eastern Europe and Northern Europe, respectively.

According to the definition for rare tumours by RARECARE (incidence < 6 per 100,000), as well as according to the definition for rare diseases by the European Commission (prevalence < 50 per 100,000) the H&N cancers described in this paper should be considered rare and diagnosis and treatment of these cancers should therefore be centralised.

© 2011 Elsevier Ltd. All rights reserved.

1. Introduction

Head and Neck (H&N) cancers are a group of tumour entities anatomically close to each other, but different in terms of aetiology, diagnostic and treatment approaches.

The most important risk factors for most H&N cancers (squamous cell carcinomas) are tobacco use and alcohol intake. In a pooled analysis, the proportion of the incidence due to tobacco and alcohol use was estimated at 72% (95% confidence interval: 61–79%) for H&N cancers (cancer of the oral cavity, oropharynx, hypopharynx, oral cavity or pharynx not otherwise specified, larynx, or head and neck cancers unspecified were included, but cancers of the major salivary glands, nasal cavity, ear and paranasal sinuses were excluded), of which 4% was due to alcohol alone, 33% was due to tobacco alone and 35% was due to tobacco and alcohol